ESMO 2022: Overall Survival Increased for Non-Small Cell Lung Cancer Patients Using Atezolizumab
Atezolizumab may offer robust treatment option in patients with non-small cell lung cancer intolerant to platinum-based chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.